Navigation Links
Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
Date:2/3/2010

PITTSBURGH, Feb. 3 /PRNewswire/ -- An era of personalized medicine is redefining how patients and doctors work together to fight cancer.  Now, drug response markers such as the ChemoFx® diagnostic test show promising results which can help to determine individual cancer treatment plans when using various chemotherapeutic agents.

ChemoFx® is a test produced by Precision Therapeutics, Inc., a life sciences company in Pittsburgh, Pennsylvania. With the introduction of this innovative drug response marker, the company has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy stage -- long before a patient actually begins chemotherapy -- providing a custom blueprint of a patient's probable tumor response.

The result is valuable insight into which chemotherapy drugs are most likely to work in an individual cancer patient's own body -- along with those that are unlikely to be effective in shrinking and killing the cancerous tumor.  This information can then be used to help guide chemotherapy treatment decisions, according to company officials.

"Patients and their physicians will have an understanding of how chemo will impact the cancer cells themselves long before it impacts the patient," says Sean McDonald, CEO of Precision Therapeutics.  "By testing multiple agents on a patient's cancer cells in the lab, ChemoFx® determines the chemotherapies that are more likely to be effective and avoid those that are likely to be ineffective, giving patients a powerful advantage in their fight against cancer."

The diagnostic test works by taking a sample of a patient's tumor, which is removed during biopsy or surgery, and sending that sample to the Precision Therapeutics laboratory for sensitivity and resistance testing. In a controlled environment that closely parallels what happens within the human body itself, those cells are incubated and treated by a fully automated system with a number of chemotherapy and biologic agents selected by that patient's physician.  Precision Therapeutics then sends the physician a report that details how the cancerous cells responded to each drug or chemotherapy combination. Integrating the results with clinical judgment, the physician can then use the report to support his decision on a treatment regimen for the patient, with the tandem objective of eradicating the disease and optimizing quality of life during chemotherapy treatment.

With the national movement toward cancer patient advocacy gaining momentum, those newly diagnosed are now engaging with their treating physician as both patient -- and partner -- in making cancer treatment decisions.  

"Today's cancer patients are informed, empowered self advocates," according to McDonald.  "They want a voice in their own treatment options.  A key discussion points is the topic of personalizing medicine through testing services such as ChemoFx.  Each and every patient's cancer is unique, making the need for individual, custom drug response markers all the more critical to support a patient's treatment plan. They want their first step to be the right step."

"When you're diagnosed with cancer, your strongest ally is information," says McDonald.  "That means talking with your doctor to plan your best course of action together.  We encourage you to test the tumor first, find out how it responds, and based on those findings and your physicians clinical judgment, determine the optimal treatment plan for your individual cancer."

About Precision Therapeutics

Precision Therapeutics, a life science company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions.

For more information, please visit www.precisiontherapeutics.com or www.ChemoFX.com

SOURCE Precision Therapeutics, Inc.

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
6. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
7. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
8. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
9. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
10. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
11. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... AvePoint, ... release of DocAve 6 Service Pack (SP) 7, the enterprise-class infrastructure ... 2016 and take advantage of the platform’s latest features – whether in an ...
(Date:5/3/2016)... ... May 03, 2016 , ... Branches, Inc. is proud to have been selected ... youth programs in South Miami. Macy’s is a wonderful community partner and has helped ... afterschool tutoring, mentoring, enrichment and academic support to elementary students 5 days a week. ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Microsoft secure remote access connectivity solutions, today announced the new SecureAccess feature ... DirectAccess. The new Celestix SecureAccess release will enable organizations to get the ...
(Date:5/3/2016)... ... ... to address a patient’s condition before it worsens will ultimately lower the cost of healthcare—and ... right thing, at the right time, at the right dose with the right patient … ... FAAFP, from Group Practice Forum. “Even if the cost of the treatment might be a ...
(Date:5/3/2016)... ... May 03, 2016 , ... Hydra Skin Sciences, a top-rated ... Allegro Anti-aging Cream, a revolutionary new anti-aging skin care product that integrates ... damaged skin, has sold over seventy-five thousand units worldwide within the first two months ...
Breaking Medicine News(10 mins):